Notably, concerning GT outcomes and cancer risk perception, our observations revealed that subsequent to the disclosure of GT results (T3), the perception of cancer risk regarding “other cancers” exhibited an escalation among women harboring BRCA1 and BRCA2 pathogenic variants, bridging the gap from Phase 2 (post-CGC, but prior to GT result disclosure). This evidence concerns the gene BRCA2 and cancer.